The invention relates to a gel-chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the gel-chewable dosage form and wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the gel-chewable dosage form.

The invention relates to a gel-chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the gel-chewable dosage form and wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the gel-chewable dosage form.

The present disclosure relates to the field of oral mucoadhesive dosage forms and the type and amounts of structural components to improve mucoadhesion. The present disclosure further relates to combinations of active ingredients within a mucoadhesive dosage form.

The subject invention relates to a novel composition for the treatment of developmental bone diseases, and other related ailments in a subject using a composition comprising an algae extract and at least one strontium salt. The subject invention also relates to two compositions for the treatment of developmental bone diseases and other related ailments in a subject by administering a composition comprising a non-viable algal culture or an extract thereof and a second composition comprising at least one strontium salt. The algae extract can comprise calcium carbonate and magnesium carbonate.

The subject invention relates to a novel composition for the treatment of developmental bone diseases, and other related ailments in a subject using a composition comprising an algae extract and at least one strontium salt. The subject invention also relates to two compositions for the treatment of developmental bone diseases and other related ailments in a subject by administering a composition comprising a non-viable algal culture or an extract thereof and a second composition comprising at least one strontium salt. The algae extract can comprise calcium carbonate and magnesium carbonate.

A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).